COMMUNIQUÉ RÉGLEMENTÉ
News
-
-
-
COMMUNIQUÉ DE PRESSE
« HK+FR: Furniture for World Design », présentée par la Hong Kong Furniture and Decoration Trade Association, s’est clôturée avec succès à Maison & Objet Paris 2025
La HKF&DA présente sa première participation réussie au salon Maison & Objet Paris 2025, mettant en avant l'innovation et l'excellence du mobilier Hongkongais -
COMMUNIQUÉ DE PRESSE
PSP Swiss Property achieves very good operating results and increases the dividend to CHF 3.90 per share.
PSP Swiss Property achieves very good operating results and increases the dividend to CHF 3.90 per share. The real estate market remained robust with improvements in transaction markets -
COMMUNIQUÉ DE PRESSE
First half of the financial year 2024/25: Strong organic growth and margin expansion continue – strategy execution on track
dormakaba Holding AG reports strong organic growth and margin expansion in the first half of the financial year 2024/25. The company's strategy execution is on track -
COMMUNIQUÉ DE PRESSE
Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®
Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®. Approval for treating retinal diseases granted by UK's MHRA -
-
COMMUNIQUÉ DE PRESSE
UniDoc - Announces Filing of Amended and Restated Interim Management Discussion and Analysis
UniDoc Health Corp. issues amended and restated management's discussion and analysis for clarifying disclosure following continuous disclosure review by the British Columbia Securities Commission -
-
COMMUNIQUÉ DE PRESSE
Onco-Innovations' PKNP Technology Shown in Study to Demonstrate Low Toxicity and High Safety Profile
Onco-Innovations Limited announces successful preclinical study results of its second-generation nanoparticle formulation of PNKP Compound, showing enhanced inhibitor delivery with minimal toxicity for potential cancer therapy
